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OBJECTIVES: The objective of this study was to analyze recent HTA decisions in 
Taiwan and Korea, and determine the influence on the outcome by HTA decision 
in Australia and the UK. METHODS: This study examined 30 high-cost drugs that 
were FDA and EMA approved from 2011-2014. Two-thirds of the sample were oncol-
ogy drugs, while the remaining one-third included drugs treating multiple sclerosis, 
chronic hepatitis C and type 2 diabetes. The HTA decisions of these products in Taiwan 
and Korea were analyzed as well as in their frequently referenced countries, Australia 
and the UK. RESULTS: Of the 30 products studied, 24 products were assessed by PBAC 
in Australia and 15 products were evaluated by NICE in the UK, while only 9 products 
received HIRA assessments in Korea and 5 products were assessed by the CDE in 
Taiwan. The difference in favorable HTA outcomes among these countries was even 
greater. Only 2 products received positive HTA decisions in Taiwan and Korea, while 
8 and 11 products were recommended in Australia and the UK respectively. Among 
the 8 products evaluated by HIRA, and previously assessed by PBAC and NICE, 6 prod-
ucts received the same decisions as PBAC and / or NICE. The correlation coefficient 
between HIRA and PBAC decisions was 0.75. Similarly, all 5 products assessed by the 
CDE received similar evaluations to those of PBAC and / or NICE, and the correla-
tion coefficient between CDE and PBAC decisions was 1. CONCLUSIONS: Access to 
medicine in Asia, even in wealthy countries like Taiwan and Korea, still largely lags 
behind Western countries like Australia and the UK. In Taiwan and Korea, where phar-
macoeconomic assessment is a key component in the HTA evaluation, HTA decisions 
may be greatly influenced by the HTA outcomes in countries like Australia and the 
UK where pharmacoeconomic evaluation is well-established.
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OBJECTIVES: Between January 2007 and September 2014 NICE report that they 
have made 65 health technology assessment decisions categorized by them as a 
“recommended in line with clinical practice” (RiLwCP). This categorization is not 
explained and implications for patient access are not clear. Using a previously 
developed method, we calculate the degree of recommended access for these deci-
sions. In order to facilitate understanding we also develop a taxonomy for the fac-
tors underlying these decisions. METHODS: In a previously published paper we 
developed a measure, M, to summarize access associated with NICE technology 
optimized appraisal decisions. This was defined as M= (p/P)X100, where M is a meas-
ure of the level of patient access (0 equals no access, 100 full access), P is the set of 
patients considered in the guidance as potential candidates for treatment (given 
the scope of appraisal and license), and p is the number of patients for whom NICE 
did recommend. We applied measure M to the 65 RiLwCP decisions made between 
January 2007 and September 2014. Then assessing the guidance documents pub-
lished for these decisions we identified six themes driving specific recommenda-
tions: reference to a previous NICE TA, existence of a relevant clinical guideline, the 
technology fits within an established pathway of care, clinical opinion, clinical/cost-
effectiveness matching, non-pharmaceutical. RESULTS: for 65 decisions between 
January 2007 and september 2014 m was 66. Among the factors underlying RiLwCP 
decisions the most common were instances where the committee matched cost 
and clinical effectiveness evidence, doing so in 37% of cases. CONCLUSIONS: The 
results for this period suggest that many RiLwCP decisions have the same charac-
teristics as those classified as “optimized” by NICE; notably that use is restricted to 
a subgroup of patients relative to license and this is done for clinical and/or cost 
effectiveness considerations.
PHP149
A comPArison of g-BA’s AdditionAl Benefit score to nice icers
Jaksa A., Liden D., Ho Y.
Context Matters, New York, NY, USA
OBJECTIVES: G-BA and NICE are two influential HTA agencies: both are large mar-
kets for pharmaceuticals, many countries look to Germany for reference pricing, 
and NICE decisions are referenced in other agencies’ assessments. Both agencies 
review clinical efficacy versus a comparator. NICE also evaluates the cost-effec-
tiveness. The output of a G-BA review is the “additional benefit” score, while for 
NICE it is an incremental cost-effectiveness ratio (ICER). Because both outcomes 
are dependent on the clinical evaluation, we hypothesize that G-BA’s additional 
benefit score and NICE’s ICER is inversely related. The relationship between NICE 
and G-BA is useful for manufacturers trying to predict reimbursement in these 
markets and globally. Our objective is to examine how G-BA’s additional benefit 
decision correlates to NICE’s reimbursement decision and to the most probable 
incremental cost-effectiveness ratio (ICER). METHODS: G-BA assessments were 
matched to NICE final guidances. G-BA’s additional benefit was extracted and 
compared to the NICE reimbursement decision (categorized as positive or nega-
tive) and the ERG’s most probable ICER. In instances where there were multiple 
ICERs reported (e.g. due to different comparators), the lowest ICER was used. If 
a drug “dominated” the comparator, an ICER of 0 was used. RESULTS: 138 G-BA 
additional benefit decisions were compared to 34 NICE final guidelines. 56% the 
G-BA assessments resulted in a “no additional benefit” score and the second most 
prevalent score was “minor additional benefit” (20%). 82% of NICE decisions were 
positive. There was no difference in the distribution of additional benefit scores by 
NICE decision. There was not a strong correlation between additional benefit and 
the ICER (r= 0.09). CONCLUSIONS: There does not appear to be a trend for G-BA 
to issue better additional benefits to drugs with a positive NICE decision and for 
drugs with a better additional benefit decision to have a lower ICER.
OBJECTIVES: The analysis was conducted to compare trends in recommenda-
tions for orphan and non-orphan products reviewed by the Scottish Medicines 
Consortium (SMC), the National Institute of Health and Care Excellence (NICE) 
and the Gemeinsamer Bundesausschuss (G-BA), and identify disease areas that 
may be particularly challenging for manufacturers planning European product 
launches. METHODS: The following were categorized as ‘recommended’: NICE 
and SMC positive and restricted recommendations, G-BA major, minor and con-
siderable additional benefit decisions; and ‘unable to recommended’: NICE nega-
tive recommendations, SMC negative recommendations and non-submissions, 
G-BA no-benefit or unquantifiable benefit. Analysis of products by disease area 
was conducted by classification into British National Formulary (BNF) catego-
ries. RESULTS: SMC, NICE and G-BA have published 1160, 147 and 100 recom-
mendations since their formation. Positive recommendations from NICE/SMC 
have increased in 2012-2014 (58% to 74%) but decreased from G-BA (50% to 43%). 
Treatments for malignant disease and immunosuppression formed the largest 
category of submissions (SMC 244, NICE 70, G-BA 34) with higher recommenda-
tion rates in Germany (65%) than the UK (50%). Significant differences in recom-
mendations between the UK and Germany were found in endocrine treatments 
(73% vs. 24%, p= 0.00003) and eye treatments (74% vs. 20%, p= 0.012). In 2011-2014, 
NICE and G-BA only evaluated 9 and 16 orphan products, respectively. Overall, 
NICE has recommended more orphan products (67%) than G-BA (63%) or SMC 
(49%). NICE and SMC recommendations for orphan products have increased in 
2014 compared to previous years. CONCLUSIONS: This analysis illustrates that 
the UK market may be easier to access than the German market but the scale of 
the challenge depends on the BNF category of the treatment. The next stage of 
analysis will consider trend analysis when accounting for SMC resubmissions and 
the re-review of NICE technology appraisals and multiple technology appraisals.
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OBJECTIVES: The statutory health insurance in Germany comprises 90% of the 
German population covering nearly all healthcare services with only little co-
payments. German health insurance claims data therefore constitute an important 
basis for real world evidence (RWE) on epidemiology and cost information. Aim 
of this study was to investigate to which extent RWE was used for estimation of 
prevalence and incidence in German AMNOG assessments since introduction 4 
years ago and also its impact on price discounts. METHODS: German AMNOG 
assessments submitted until December 2014 were evaluated. They were screened 
for use of RWE in assessing prevalence and incidence and also target populations. 
After description and discussion of methods and data sources used, statistics 
were applied to explore a potential influence of use and quality of RWE data on 
price discounts. RESULTS: In total, 108 AMNOG dossiers were included. Real world 
evidence was used in 42.6% of these dossiers to assess prevalence and incidence 
as well as target populations. German claims data were employed in 8 dossiers 
(7.4%), registry data in 7 dossiers (6.5%), other data sources like Delphi panels 
in 37 dossiers (34.3%). The impact of quality of RWE evidence on negotiated dis-
counts is inconclusive with limited data available. German claims data comprise 
comprehensive information such as demographics, outpatient and inpatient care, 
prescriptions, devices and aids, incapacity to work and sick leave payments. The 
routine documentation of diagnoses, procedures and prescriptions as well as the 
ability to evaluate patient histories are particularly useful for prevalence and 
incidence analyses, especially regarding the target population and cost estima-
tions which are of paramount importance in price negotiations following the 
AMNOG assessment. CONCLUSIONS: German claims data constitute a valuable 
and valid data source for assessing epidemiologic evidence in German AMNOG 
assessments. Indication specific claims data analyses are a meaningful comple-
ment to literature research.
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OBJECTIVES: Meta-analysis (MA) of time to event survival data are most commonly 
performed using the individual summary statistic hazard ratio from each study, as 
an appropriate measure of effect. Currently there is no clear guidance regarding 
alternative novel methodologies of evidence synthesis using survival data which 
violates the proportional hazards (PH) assumption. The aim of this study was to 
assess: (i) the guidance from HTA bodies in relation to the MA of time to event 
survival data; (ii) technology assessments (TAs) submitted to NICE to determine 
the level of supporting information relating to the PH assumption accompany-
ing MAs of time to event data in manufacturer submissions, and the response of 
reimbursement authorities. METHODS: HTA authorities guidelines (NICE, PBAC, 
IQWIG, CADTH, NCPE) were searched to identify information relating to the MA 
of time to event data. The NICE website was interrogated to identify TAs and the 
associated ERG/FAD reports in the oncology setting (published 2011–2014) report-
ing MAs of time to event data. RESULTS: Of the guidelines searched, the NICE, 
PBAQ and IQWIG guidelines for evidence synthesis refer to the consideration of the 
proportional hazards assumption when performing MA of time to event survival 
data. Of the most recent 60 NICE TAs, seven included the analysis of time to event 
data, however none commented upon the PH assumption. CONCLUSIONS: The 
impact of failing to consider the validity of the PH assumption for MA of time to 
event data in manufacturer submissions is unclear. The failure of trialists and 
statisticians to investigate the validity of the PH assumption for time to event 
data used in evidence synthesis may result in clinical decisions based on inap-
propriate methods.
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manufacturers. There are several options for remedy such as a more comprehensive 
product review programme, but this could lead to further delays.
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Access to medicine, reimBursement And Pricing in germAny: wHAt 
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OBJECTIVES: Since the health care reform in Germany (AMNOG) in 2011, newly 
approved drugs have to demonstrate their innovation to avoid reference group 
pricing. The pharmaceutical manufacturer (PM) has to submit a dossier proving 
additional benefit versus the appropriate comparator recommended by the G-BA 
(Joint Federal Committee). METHODS: Benefit assessments and G-BA decisions 
to date were analyzed. Outcome data, indirect comparisons and decisions (until 
January 2015) were explored with regard to factors potentially impacting the out-
come of price negotiations. RESULTS: 148 agents entered the assessment process, 
102 dossier completed the whole assessment process. G-BA evaluations resulted 
in 26 minor, 21 considerable, and 55 not quantifiable/no additional therapeutic 
benefit of assessed vs. comparator drug. In 29 cases the G-BA did not follow IQWiG’s 
conclusions of the extent of additional benefit. The choice of appropriate com-
parator was controversial between G-BA and PM in 10 cases, followed by questions 
about evidence of benefit. 5 drugs, which failed to prove an additional benefit, were 
withdrawn from the German market. In a sub-analysis 18 drugs were examined, 
where the reimbursed price has been negotiated between the National Association 
of Statutory Health Insurance Funds (GKV-SV) and PM. The mean rebate was 17% 
with a range from 0 to 52%. Negotiated rebates were not correlated with any of the 
clinical and economic parameters (e.g. number of patients benefitting, proposed 
price) analyzed. CONCLUSIONS: AMNOG mediates price control despite mandatory 
reimbursement of innovative drugs. Following initial pitfalls in dossier develop-
ment the withdrawal of 5 drugs in 2012 may indicate that nowadays either the PMs 
are more familiar with AMNOG or, that drugs with limited potential of proving an 
additional benefit tend to be not launched in Germany. The majority of price nego-
tiations resulted in reductions of < 20%. It was not possible to identify parameters 
predicting the magnitude of rebates.
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OBJECTIVES: Early market access schemes are expanding across the globe, pre-
senting health technology suppliers with a variety of opportunities for expediting 
product approval. This paper aims to provide an overview of three such schemes: 
the ‘conditional approval’ opportunity in Japan’s Pharmaceuticals, Medical Devices 
and Other Therapeutic Products (PMD) Act; the UK’s Early Access to Medicines 
Scheme (EAMS); and the Breakthrough Therapy (BT) designation program in 
the US. METHODS: Secondary research identified market-specific early access 
schemes and key themes were evaluated. Where available, quantitative data were 
analyzed. Hypotheses were generated and then validated during in-depth inter-
views with key stakeholders across markets. RESULTS: The US BT designation 
is the most advanced early access opportunity, having been established in July 
2012. Of the 212 technologies reviewed so far, 35% have gained BT status. Through 
December 2014, 16 have subsequently obtained full approval. Launched in the 
UK in April 2014, the EAMS has had three promising innovative medicine (PIM) 
designations, which forms the first of two steps in gaining early market access. In 
Japan, the conditional approval scheme focuses on regenerative medicines and, 
while interest is significant, the program is in its infancy, having been formalized 
in November 2014. CONCLUSIONS: Health technology suppliers need to evaluate 
associated costs and benefits when determining whether any of the early access 
routes are appropriate for a novel product. One consideration is the type of tech-
nology in scope: developers of regenerative cell therapies should consider the 
Japanese scheme, but will need to leverage local partnerships in order to facilitate 
access. Another consideration is the costs involved in application, and whether the 
technology is reimbursed during the program. While products are reimbursed in 
Japan, UK reimbursement is not guaranteed. The BT program is the most mature 
and globally recognized of the three, and offers ongoing regulatory support until 
final marketing authorization.
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OBJECTIVES: HTA agencies in both Germany (IQWiG) and France (TC) focus on 
additional benefits without explicit consideration of cost in their HTA assessment. 
While the German Federal Joint Committee (GBA) usually commissions IQWiG for 
the assessment, the GBA makes final decisions on the level of additional benefit 
provided by a new therapy. We sought to document whether the GBA and TC 
reached the same rankings for the same drug indication evaluated. METHODS: 
We first searched GBA assessments conducted from August 2011 to July 2014 and 
then cross checked whether the TC completed its own assessment for the same 
indication. The GBA classifies additional benefits as “Major, Considerable, Minor, 
Non-quantifiable, No Benefit, and Less Benefit”. For the TC, they are categorized as 
“Major, Important, Significant, Minor, No Improvement, Do Not Recommend”. We 
also examined the comparators used in the assessments. RESULTS: A total of 67 
indications were evaluated by both agencies. No indication was awarded “Major” 
by either agency. For 17 “Considerable” ranking granted by the GBA, 2 were given 
“Important”, 8 “Significant”, 6 “Minor”, and 1 “No Improvement” by the TC. For 21 
“Minor” ranking awarded by the GBA, 1 was considered “Significant”, 11 “Minor”, 
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OBJECTIVES: Under the positive drug listing system, pharmaceutical companies in 
Korea are required to provide cost-effectiveness (CE) evidence of newly approved 
drugs for listing on the National Health Insurance (NHI) drug formulary. It has been 
argued that selection criteria of comparator treatments suggested by the CE guide-
line are too limited and unrealistic to conduct a valid CE assessment. Therefore, 
our study was conducted to investigate types of practical problems in comparator 
selection in order to improve the validity of CE analysis. METHODS: We conducted 
focus group interviews (FGI) with experts working in research-based drug compa-
nies, charged of submitting CE evidence of their products to NHI. Each participant 
received an interview question via an e-mail beforehand and presented their opin-
ions at round-table discussion. RESULTS: Examples of the problems associated with 
selecting appropriate comparators identified from FGI are as follows: drugs with 
the same indication, but therapeutically nonequivalent, were used as comparators ; 
there is no guidance on whether to include off-label drugs as comparators; when off-
patent products were selected as comparators, the price of the new drug was com-
pared with the price of generic products rather than the initial price of the original 
products set during the patent period; it is difficult to obtain reliable market share 
data needed for selecting a comparator; and the best supportive care was selected as 
a comparator when there’s no appropriate treatment alternatives. CONCLUSIONS: 
We expect that the results of our investigation would contribute to improve the 
quality of CE guidelines in South Korea as well as other countries, and to improve 
assessment of the true value of pharmaceutical intervention.
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PerformAnce meAsures of good PrActices in HtA Be identified?
WANG T.
CIRS, London, UK
OBJECTIVES: To establish a working definition of “quality” in the HTA context; to 
identify the key features of good-quality HTA submission and review performance. 
The outcome of the research will be used to facilitate the development and adoption 
of best practices in HTA submissions, assessment processes and decision mak-
ing. METHODS: The research was initiated by identifying common elements that 
underpin a quality submission dossier, and a set of key performance indicators 
(KPIs) of HTA review processes and procedures. International experts representing 
HTA/coverage agencies, academics and pharmaceutical companies were invited 
to discuss the identified parameters from diverse viewpoints. The key discussion 
points and recommendations for KPIs are outlined herein. RESULTS: Four elements 
of a quality dossier were identified: robustness and relevance of the scientific data; 
dossier completeness, that is, the inclusion of all relevant information; integrity or 
consistency; and logical structure and clear format. Quality of HTA review is most 
easily measured by assessing outcomes of tools designed to ensure or to support 
good-quality process such as internal and external peer reviews, audits, standard 
operating procedures and procedures for learning and feedback. Ten KPIs of the HTA 
review process considered important from a company’s perspective were identified 
as well the four main areas from HTA agencies perspective: timeliness, relevance, 
credibility and impact. CONCLUSIONS: A key outcome of this research was a clear 
understanding of “quality” in the context of HTA across stakeholders, and the iden-
tification of key factors, irrespective of the diversity of HTA agencies, which could 
be used to measure the quality of process. The next phase of the research will be to 
develop an instrument to measure quality of HTA process based on identified KPIs 
and to be piloted and validated by key stakeholders.
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OBJECTIVES: In contrast to the Scottish Medicines Consortium, NICE does not 
evaluate all new medicines, but uses a set of specific selection criteria. Where a 
technology is not selected for assessment the affected products may face difficul-
ties in achieving payer and physician uptake. We aim to demonstrate and evaluate 
the difficulties faced by those seeking market access for products and the conse-
quence of non-selection. Whilst oncology products currently have the Cancer Drugs 
Fund (CDF) to fall back on, there is an issue of how NICE, CDF and NHS England 
policies will work together in the future. We further consider the possible options, 
both for delaying and non-assessment, or failure to obtain reimbursement through 
other routes. METHODS: We review the topic selection methodologies and com-
pare the number of marketing authorizations approved in recent years and those 
products reviewed by NICE. Examples of orphan drugs that have not been selected 
are provided. We further review opportunities for redress for the manufacturer 
where they are not subject to a technology appraisal. RESULTS: The position of a 
company seeking reimbursement for a new product that has not been reviewed 
by NICE is precarious, forcing them to rely on NHS England policies, local com-
missioner approvals, individual hospitals within CCGs or, ultimately, legal redress. 
Currently, there are over 20 NHS England policies to support the commissioning 
of products, and services associated with those products; and over 100 awaiting 
review. The common characteristic accompanying success is strong clinical support 
from the relevant NHS England clinical reference group and powerful patient lob-
bying. CONCLUSIONS: The current position, whether caused by delay or a positive 
decision by NICE not to review, is considered unsatisfactory both for patients and 
